drugset
drugset / Trial / NCT00872196

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

NCT00872196 ↗

Phase 2 Completed 5 enrolled AbbVie
NaSingle-groupOpen-label

Summary

This is a follow-up study with no treatment and only samples being collected.

Timeline

Start
2009-04
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Background ABT-072 Small molecule — —

Indications

hepatitis C virus infection